Selectis Health, Inc. (GBCS) Fair Value 2026

GBCS · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 5 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-27, Selectis Health, Inc. (GBCS) trades at $5.42, versus a $17.64 median fair value across its 5 active models — 225.4% above the current price. QOC: 5.9/10. Value Trap Risk: 12/100 (SAFE). 5/13 models active.

Key Facts

Ticker
GBCS
Price
$5.42
Quality Score
5.9/10
Value Trap Risk
12/100
Models Active
5/13
Last Updated
Strength: ML-RIV suggests +376.1% upside with 52% confidence
Risk: Limited model coverage (5/13) may reduce confidence

Is Selectis Health, Inc. (GBCS) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Selectis Health, Inc. (GBCS) appears undervalued as of : the median of 5 independent fair value estimates is $17.64, 225.4% above the current price of $5.42. Estimates range from $8.05 to $25.80. GBCS scores 5.9/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. GBCS’s +225.4% gap is wider than that market norm, and the Medical Care Facilities sector median is -28.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Selectis Health, Inc. Stock in 2026? →

What Fair Value Does Each Model Give GBCS?

5 Intrinsic Value Models vs. Current Price ($5.42)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $17.64 +225.4%
Intrinsic · High Conviction
 $25.80 +376.1%
Unlock the Full Matrix

Access 3 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is GBCS's Fair Value Range?

Spread across 5 independent models · $8.05 to $25.80

CirclFi's 5 active models place Selectis Health, Inc. (GBCS) between $8.05 and $25.80 per share, a spread of 101% of the median. The median of that range — $17.64 — is the fair value CirclFi publishes for GBCS, against a current price of $5.42.

Low · PWERMHigh · ML-RIV
$8.05median $17.64$25.80
Where the range comes from
Most bearish modelPWERM$8.05
Most bullish modelML Residual Income$25.80
Model agreement5 bullish · 0 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for GBCS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on GBCS, not a CirclFi price target. How each model works →

What Is Selectis Health, Inc. (GBCS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Selectis Health, Inc. is potentially undervalued at its current price of $5.42. Based on our 13-model framework, Selectis Health, Inc.'s intrinsic value is estimated at a median fair value of $17.64 — representing +225.4% implied upside — with 5 out of 5 active models confirming this thesis. Model dispersion is worth noting: ML-RIV targets $25.80 (+376.1%), versus PWERM at $8.05 (+48.5%). This +327.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About GBCS?

5 of 13 models are currently active for GBCS. All 5 active models suggest the stock trades below fair value. Taken together, their median fair value for GBCS is $17.64 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does GBCS Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, GBCS ranks #40 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Medical Care Facilities Stocks →

Selectis Health, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is GBCS a Value Trap?

CirclFi's Value Trap algorithm assigns GBCS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Selectis Health, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Selectis Health, Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +327.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GBCS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GBCS's 5 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Selectis Health, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

11 related Medical Care Facilities stocks with 13-model coverage

AGLagilon health, inc.QOC 5.9AMSAmerican Shared Hospital ServicesQOC 5.9SYRASyra Health Corp.QOC 5.9EHSIElite Health Systems Inc.QOC 5.8CCMConcord Medical Services Holdings LimitedQOC 6.1BKDBrookdale Senior Living Inc.QOC 5.7FOXOFOXO Technologies Inc.QOC 3.9CHEChemed CorporationQOC 8.2ASTHAstrana Health, Inc.QOC 7.1ADUSAddus HomeCare CorporationQOC 8.9NHCNational HealthCare CorporationQOC 8.7

Read investment analysis: AGL · AMS · SYRA · EHSI · CCM · BKD · FOXO · CHE · ASTH · ADUS · NHC

Which Other Stocks Have a Similar Quality Score to GBCS?

7 companies across all industries closest to GBCS’s Quality of Company score of 5.9/10.

QUBTQuantum Computing Inc.QOC 5.9TYGOTigo Energy, Inc.QOC 5.9RLAYRelay Therapeutics, Inc.QOC 5.9FOSLFossil Group, Inc.QOC 5.9HAFGHolistic Asset Finance Group Co., Ltd.QOC 5.9BDNBrandywine Realty TrustQOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: QUBT · TYGO · RLAY · FOSL · HAFG · BDN · NVDA

Where Does GBCS Sit in CirclFi's Medical Care Facilities Rankings?

GBCS is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About Selectis Health, Inc.’s Valuation?

What is Selectis Health, Inc.'s intrinsic value in 2026?

CirclFi puts Selectis Health, Inc. (GBCS)'s intrinsic value at $17.64 — the median of 5 independent model estimates as of 2026-08-27, ranging from $8.05 to $25.80. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GBCS overvalued or undervalued right now?

At $5.42, 5 of 5 active models suggest GBCS may be undervalued, while 0 indicate potential overvaluation. The median of all 5 fair value estimates is $17.64, 225.4% above the current price of $5.42 — a consensus view that GBCS is undervalued. The assessment depends on which methodology best fits Selectis Health, Inc.'s business model in Medical Care Facilities.

What does a Quality of Company score of 5.9 mean for GBCS?

Selectis Health, Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on GBCS?

CirclFi analyzes GBCS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on GBCS?

Of the 5 models currently active on GBCS, ML Residual Income is the most bullish at $25.80 per share, and PWERM is the most bearish at $8.05. CirclFi's published fair value for GBCS is the median of that range, $17.64, not either extreme. The gap between the two ends equals 101% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is GBCS a value trap in 2026?

Selectis Health, Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Selectis Health, Inc. (GBCS) has a median fair value of $17.64 — 225.4% above the current price of $5.42 — as of 2026-08-27.” Source: circlfi.com/stock/GBCS/ · Methodology
Primary sources for this GBCS valuation
  • Financial statements: Selectis Health, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000727346) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GBCS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on GBCS.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for GBCS Unlock All 5 — $39/mo